Archivum Immunologiae et Therapiae Experimentalis

, Volume 60, Issue 1, pp 31–41

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status

Review

Abstract

Hematopoietic cell transplantation (HCT) offers potentially curative therapy for patients with myelodysplastic syndrome (MDS). However, as the majority of patients with MDS is in the 7th or 8th decade of life, only few of these patients were transplanted following high-dose conditioning regimens. The development of reduced-intensity conditioning has allowed to apply HCT also to older patients and those with clinically relevant comorbid conditions. Dependent upon disease status and the type of clonal chromosomal abnormalities present at the time of HCT, some 25–75% of patients will be cured of their disease and survive long term. Recent results with HLA-matched unrelated donors are comparable to those with HLA genotypically identical siblings. The increasing use of cord blood and HLA-haploidentical donors is expected to make HCT available to a growing number of patients. However, post-transplant relapse and graft-versus-host disease remain problems requiring further instigations.

Keywords

Transplantation for MDS Age Comorbidities Conditioning intensity Relapse 

References

  1. Al-Ali HK, Brand R, van Biezen A et al (2007) A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 21:1945–1951PubMedGoogle Scholar
  2. Alessandrino EP, Della Porta MG, Bacigalupo A et al (2008) WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112:895–902PubMedGoogle Scholar
  3. Alyea EP, Kim HT, Ho V et al (2006) Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12:1047–1055PubMedGoogle Scholar
  4. Armand P, Kim HT, Cutler CS et al (2007a) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586–4588PubMedGoogle Scholar
  5. Armand P, Kim HT, DeAngelo DJ et al (2007b) Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 13:655–664PubMedGoogle Scholar
  6. Armand P, Kim HT, Cutler CS et al (2008) A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14:28–35PubMedGoogle Scholar
  7. Armand P, Deeg HJ, Kim HT et al (2010) Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant 45:877–885PubMedGoogle Scholar
  8. Aversa F (2008) Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States (Review). Bone Marrow Transplant 41:473–481PubMedGoogle Scholar
  9. Bacher U, Zander AR, Haferlach T et al (2008) Minimal residual disease diagnostics in myeloid malignancies in the post transplant period (Review). Bone Marrow Transplant 42:145–157PubMedGoogle Scholar
  10. Barker JN, Weisdorf DJ, Defor TE et al (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105:1343–1347PubMedGoogle Scholar
  11. Baron F, Sandmaier BM (2005) Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 12:435–443PubMedGoogle Scholar
  12. Bartenstein M, Deeg HJ (2010) Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 24:407–422PubMedGoogle Scholar
  13. Beelen DW, Trenschel R, Casper J et al (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35:233–241PubMedGoogle Scholar
  14. Beran M (2000) Intensive chemotherapy for patients with high-risk myelodysplastic syndrome (Review). Int J Hematol 72:139–150PubMedGoogle Scholar
  15. Breccia M, Cannella L, Stefanizzi C et al (2009) WPSS versus simplified myelodysplastic syndrome risk score: which is the best tool for prediction of survival in myelodysplastic patients? Leuk Res 33:e93–e94PubMedGoogle Scholar
  16. Brunstein CG, Weisdorf DJ (2009) Future of cord blood for oncology uses (Review). Bone Marrow Transplant 44:699–707PubMedGoogle Scholar
  17. Brunstein CG, Gutman JA, Weisdorf DJ et al (2010) Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693–4699PubMedGoogle Scholar
  18. Busca A, Falda M, Manzini P et al (2010) Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant 16:115–122PubMedGoogle Scholar
  19. Campregher PV, Gooley T, Scott BL et al (2007) Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 40:965–971PubMedGoogle Scholar
  20. Casper J, Wolff D, Knauf W et al (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28:3344–3351PubMedGoogle Scholar
  21. Castro-Malaspina H, Harris RE, Gajewski J et al (2002) Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943–1951PubMedGoogle Scholar
  22. Cazzola M, Della Porta MG, Malcovati L (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes (Review). Hematology Am Soc Hematol Educ Program 2008:166–175Google Scholar
  23. Chang C, Storer BE, Scott BL et al (2007) Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110:1379–1387PubMedGoogle Scholar
  24. Cutler CS, Lee SJ, Greenberg P et al (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579–585PubMedGoogle Scholar
  25. de Lima M, Giralt S (2006) Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome (Review). Semin Hematol 43:107–117PubMedGoogle Scholar
  26. de Lima M, Anagnostopoulos A, Munsell M et al (2004a) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865–872PubMedGoogle Scholar
  27. de Lima M, Couriel D, Thall PF et al (2004b) Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104:857–864PubMedGoogle Scholar
  28. de Lima M, Giralt S, Thall PF et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420–5431PubMedGoogle Scholar
  29. De Padua SL, de Lima M, Kantarjian H et al (2009) Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43:839–843Google Scholar
  30. De Roos AJ, Deeg HJ, Onstad L et al (2010) Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005–2006. Am J Hematol 85:765–770PubMedGoogle Scholar
  31. de Witte T, Hermans J, Vossen J et al (2000) Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620–630PubMedGoogle Scholar
  32. de Witte T, Brand R, van Biezen A et al (2009) Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 146:627–636PubMedGoogle Scholar
  33. Deeg HJ (2009a) Hematopoietic cell transplantation for myelodysplastic syndrome and myeloproliferative disorders. In: Appelbaum FR, Forman SJ, Negrin RS et al (eds) Thomas’ hematopoietic cell transplantation. Wiley-Blackwell, Oxford, pp 827–844Google Scholar
  34. Deeg HJ (2009b) Transplant conditioning regimens: can we say it better? (Editorial). Biol Blood Marrow Transplant 15:653–655PubMedGoogle Scholar
  35. Deeg HJ, Sandmaier BM (2010) Who is fit for allogeneic transplantation? Blood 116:4762–4770PubMedGoogle Scholar
  36. Deeg HJ, Storer B, Slattery JT et al (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201–1207PubMedGoogle Scholar
  37. Deeg HJ, Maris MB, Scott BL et al (2006) Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 20:1701–1705PubMedGoogle Scholar
  38. Delaney C, Gutman JA, Appelbaum FR (2009) Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications (Review). Br J Haematol 147:207–216PubMedGoogle Scholar
  39. Depil S, Deconinck E, Milpied N et al (2004) Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33:531–534PubMedGoogle Scholar
  40. Diez-Campelo M, Perez-Simon JA, Perez J et al (2009) Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 84:149–152PubMedGoogle Scholar
  41. Farina L, Bruno B, Patriarca F et al (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 23:1131–1138PubMedGoogle Scholar
  42. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232PubMedGoogle Scholar
  43. Gattermann N (2009) The treatment of secondary hemochromatosis. Dtsch Arztebl Int 106:499–504PubMedGoogle Scholar
  44. Gooley TA, Chien JW, Pergam SA et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091–2101PubMedGoogle Scholar
  45. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 [erratum appears in Blood 1998 91:1100]PubMedGoogle Scholar
  46. Greenberg PL, Baer MR, Bennett JM et al (2006) Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:58–77 [erratum appears in J Natl Compr Canc Netw 2006 Mar 4(3):table of contents Note: dosage error in text]PubMedGoogle Scholar
  47. Guardiola P, Runde V, Bacigalupo A et al (2002) Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99:4370–4378PubMedGoogle Scholar
  48. Guilfoyle R, Demers A, Bredeson C et al (2009) Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 43:133–139PubMedGoogle Scholar
  49. Hamblin TJ (2002) Epidemiology of the myelodysplastic syndromes. In: Bennett JM (ed) The myelodysplastic syndromes: pathobiology and clinical management. Marcel Dekker, Inc, New York, pp 15–27Google Scholar
  50. Harrison SJ, Cook G, Nibbs RJ et al (2006) Immunotherapy of multiple myeloma: the start of a long and tortuous journey (Review). Expert Rev Anticancer Ther 6:1769–1785PubMedGoogle Scholar
  51. Kang Y, Chao NJ, Aversa F (2008) Unmanipulated or CD34 selected haplotype mismatched transplants (Review). Curr Opin Hematol 15:561–567PubMedGoogle Scholar
  52. Kantarjian H, O’Brien S, Ravandi F et al (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351–1361PubMedGoogle Scholar
  53. Kasamon YL, Luznik L, Leffell MS et al (2010) Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16:482–489PubMedGoogle Scholar
  54. Kataoka K, Nannya Y, Hangaishi A et al (2009) Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15:195–204PubMedGoogle Scholar
  55. Kataoka K, Nannya Y, Ueda K et al (2010) Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant 45:513–520PubMedGoogle Scholar
  56. Kawase T, Matsuo K, Kashiwase K et al (2009) HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 113:2851–2858PubMedGoogle Scholar
  57. Kelly SS, Sola CB, de Lima M et al (2009) Ex vivo expansion of cord blood (Review). Bone Marrow Transplant 44:673–681PubMedGoogle Scholar
  58. Kindwall-Keller T, Isola LM (2009) The evolution of hematopoietic SCT in myelodysplastic syndrome (Review). Bone Marrow Transplant 43:597–609PubMedGoogle Scholar
  59. Koh LP, Chao NJ (2004) Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens (Review). Biol Blood Marrow Transplant 10:1–22PubMedGoogle Scholar
  60. Laport GG, Sandmaier BM, Storer BE et al (2008) Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 14:246–255PubMedGoogle Scholar
  61. Lee JW, Kang HJ, Kim EK et al (2009) Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 44:793–797PubMedGoogle Scholar
  62. Lee JH, Lee JH, Lim SN et al (2010) Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant 45:450–457PubMedGoogle Scholar
  63. Lim ZY, Ho AY, Ingram W et al (2006) Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 135:201–209PubMedGoogle Scholar
  64. Lim ZY, Pearce L, Ho AY et al (2007) Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 138:517–526PubMedGoogle Scholar
  65. Litzow MR, Tarima S, Perez WS et al (2010) Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115:1850–1857PubMedGoogle Scholar
  66. Luznik L, O’Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641–650PubMedGoogle Scholar
  67. Mahindra A, Bolwell B, Sobecks R et al (2009) Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 146:310–316PubMedGoogle Scholar
  68. Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510PubMedGoogle Scholar
  69. Maradei SC, Maiolino A, de Azevedo AM et al (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 114:1270–1275PubMedGoogle Scholar
  70. Marcondes M, Deeg HJ (2008) Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? Best Pract Res Clin Haematol 21:67–77PubMedGoogle Scholar
  71. Maris MB, Sandmaier BM, Storer BE et al (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535–3542PubMedGoogle Scholar
  72. Martino R, Iacobelli S, Brand R et al (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836–846PubMedGoogle Scholar
  73. Michalek J, Collins RH, Durrani HP et al (2003) Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 100:1180–1184PubMedGoogle Scholar
  74. Mills KI, Kohlmann A, Williams PM et al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063–1072PubMedGoogle Scholar
  75. Nachtkamp K, Kundgen A, Strupp C et al (2009) Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33:1024–1028PubMedGoogle Scholar
  76. Nakai K, Kanda Y, Fukuhara S et al (2005) Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19:396–401PubMedGoogle Scholar
  77. Nemecek ER, Guthrie KA, Sorror ML et al (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17:341–350PubMedGoogle Scholar
  78. O’Donnell P, Luznik L, Symons H (2006) Favorable outcome of patients with relapsed Hodgkin lymphoma (HL) after nonmyeloablative hematopoietic cell transplantation (NM-HCT) using related haploidentical donors. Blood 108(Part 1):894a–895a #3135 (Abstract)Google Scholar
  79. O’Donnell PV, Harrington E, Gooley TA et al (2010) Cyclophosphamide-induced tolerance following bone marrow transplantation from haploidentical donors. Haematologica Edición Española 95(Extra 1):266–271Google Scholar
  80. Oliansky DM, Antin JH, Bennett JM et al (2009) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 15:137–172PubMedGoogle Scholar
  81. Ooi J (2006) The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 47:599–602PubMedGoogle Scholar
  82. Ooi J, Iseki T, Takahashi S et al (2003) Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 101:4711–4713PubMedGoogle Scholar
  83. Parimon T, Au DH, Martin PJ et al (2006) A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144:407–414PubMedGoogle Scholar
  84. Petersdorf EW (2009) Hematopoietic cell transplantation from unrelated donors. In: Appelbaum FR, Forman SJ, Negrin RS et al (eds) Blume thomas’ hematopoietic cell transplantation. Wiley-Blackwell, Oxford, pp 675–691Google Scholar
  85. Pidala J, Anasetti C, Kharfan-Dabaja MA et al (2009a) Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15:1415–1421PubMedGoogle Scholar
  86. Pidala J, Kim J, Field T et al (2009b) Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 15:1116–1121PubMedGoogle Scholar
  87. Ramakrishnan A, Deeg HJ (2008) Allogeneic hematopoietic cell transplantation for patients with myelodysplastic syndrome and myeloproliferative disorders. In: Soiffer RJ (ed) Hematopoietic stem cell transplantation. Humana Press, Totowa, pp 167–182Google Scholar
  88. Rizzieri DA, Koh LP, Long GD et al (2007) Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25:690–697PubMedGoogle Scholar
  89. Rocha V, Gluckman E (2009) Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 147:262–274PubMedGoogle Scholar
  90. Rocha V, Locatelli F (2008) Searching for alternative hematopoietic stem cell donors for pediatric patients (Review). Bone Marrow Transplant 41:207–214PubMedGoogle Scholar
  91. Samuelson S, Sandmaier BM, Heslop HE et al (2011) Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age. Br J Haematol 153:76–82PubMedGoogle Scholar
  92. Sato A, Ooi J, Takahashi S et al (2011) Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 46:257–261PubMedGoogle Scholar
  93. Scott B, Deeg HJ (2006) Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol 19:519–522PubMedGoogle Scholar
  94. Scott BL, Storer B, Loken M et al (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65–73PubMedGoogle Scholar
  95. Scott BL, Sandmaier BM, Storer B et al (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20:128–135PubMedGoogle Scholar
  96. Scott BL, Storer BE, Greene JE et al (2007) Marrow fibrosis as a risk factor for post-transplant outcome in patients with advanced MDS or AML with multilineage dysplasia. Biol Blood Marrow Transplant 13:345–354PubMedGoogle Scholar
  97. Scott BL, Wells DA, Loken MR et al (2008) Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112:2681–2686PubMedGoogle Scholar
  98. Shaw BE, Mufti GJ, Mackinnon S et al (2008) Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 42:783–789PubMedGoogle Scholar
  99. Sierra J, Pérez WS, Rozman C et al (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997–2004PubMedGoogle Scholar
  100. Sorror M, Maris M, Baron F (2004) A modified hematopoietic cell transplantation (HCT)-specific co-morbidity index. Blood 104(Part 1):324a–325a #1146 (Abstract)Google Scholar
  101. Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919PubMedGoogle Scholar
  102. Sorror M, Storer B, Sandmaier BM et al (2008) Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112:1992–2001PubMedGoogle Scholar
  103. Spitzer TR (2005) Haploidentical stem cell transplantation: the always present but overlooked donor. Hematol Am Soc Hematol Educ Program 2005:390–395Google Scholar
  104. Steensma DP, Bennett JM (2006) The myelodysplastic syndromes: diagnosis and treatment (Review). Mayo Clin Proc 81:104–130PubMedGoogle Scholar
  105. Stetler-Stevenson M, Arthur DC, Jabbour N et al (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98:979–987PubMedGoogle Scholar
  106. Strasser SI, Kowdley KV, Sale GE et al (1998) Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 22:167–173PubMedGoogle Scholar
  107. Sucak GT, Yegin ZA, Ozkurt ZN et al (2008) The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant 42:461–467PubMedGoogle Scholar
  108. Valcarcel D, Martino R (2007) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia (Review). Curr Opin Oncol 19:660–666PubMedGoogle Scholar
  109. Vaughn J, Storer B, Mielcarek M et al (2010) Treatment of recurrent or persistent AML/MDS after allogeneic hematopoietic cell transplantation with azacitidine. Blood 116:551 #1288 (Abstract)Google Scholar
  110. Warlick ED, O’Donnell PV, Borowitz M et al (2008) Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res 32:1439–1447PubMedGoogle Scholar
  111. Warlick ED, Cioc A, DeFor T et al (2009) Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 15:30–38PubMedGoogle Scholar
  112. Wells DA, Benesch M, Loken MR et al (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood 102:394–403PubMedGoogle Scholar
  113. Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation (Review). Annu Rev Immunol 25:139–170PubMedGoogle Scholar
  114. Yakoub-Agha I, de La Salmonière P, Ribaud P et al (2000) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J Clin Oncol 18:963–971PubMedGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2011

Authors and Affiliations

  1. 1.Fred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.University of Washington School of MedicineSeattleUSA

Personalised recommendations